A randomized, double blind, placebo-controlled, parallel group study evaluating effects of intranasal JNJ-17166864 on symptoms of allergic rhinitis in adult men or women allergic to mountain cedar pollen

Trial Profile

A randomized, double blind, placebo-controlled, parallel group study evaluating effects of intranasal JNJ-17166864 on symptoms of allergic rhinitis in adult men or women allergic to mountain cedar pollen

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2014

At a glance

  • Drugs JNJ 17166864 (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 28 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Apr 2010 Actual patient number (74) added as reported by ClinicalTrials.gov.
    • 03 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top